Drug
Bortezomib, Lenalidomide, Dexamethasone
Bortezomib, Lenalidomide, Dexamethasone is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph phase_4
2
67%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
Not yet recruiting1
unknown1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 21 (33.3%)
Phase 42 (66.7%)
Trials by Status
not_yet_recruiting133%
unknown133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
not_yet_recruitingphase_4
Isa-VRD in TIE HRMM
NCT07334535
recruitingphase_4
Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)
NCT07025005
unknownphase_2
Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma
NCT04277845
Clinical Trials (3)
Showing 3 of 3 trials
NCT07334535Phase 4
Isa-VRD in TIE HRMM
NCT07025005Phase 4
Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)
NCT04277845Phase 2
Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3